| Literature DB >> 31666080 |
Jonathan M Carnino1, Heedoo Lee1, Yang Jin2.
Abstract
Extracellular vesicles (EVs) are cell-derived membranous vesicles secreted by cells into the extracellular space, which play a role in cell to cell communication. EVs are categorized into 3 groups depending on their size, surface marker, and method of release from the host cell. Recently, EVs have become of interest in the study of multiple disease etiologies and are believed to be potential biomarkers for many diseases. Multiple different methods have been developed to isolate EVs from different samples such as cell culture medium, serum, blood, and urine. Once isolated, EVs can be characterized by technology such as nanotracking analysis, dynamic light scattering, and nanoscale flow cytometry. In this review, we summarize the current methods of EV isolation, provide details into the three methods of EV characterization, and provide insight into which isolation approaches are most suitable for EV isolation from bronchoalveolar lavage fluid (BALF).Entities:
Keywords: Apoptotic body; Bronchoalveolar lavage fluid (BALF); Exosome; Extracellular vesicle (EV); Microvesicle
Mesh:
Substances:
Year: 2019 PMID: 31666080 PMCID: PMC6822481 DOI: 10.1186/s12931-019-1210-z
Source DB: PubMed Journal: Respir Res ISSN: 1465-9921
Fig. 1Schema of Each Major Category of EV. Schema highlighting the key difference in size and method of production between the three categories of EVs: Microvesicles, Exosomes, and Apoptotic Bodies. MBV: membrane-bound nanovesicles
Partial Current Literature on BALF-EVs in Lung Diseases
| Diseases/processes | Main conclusion | Author/Journal |
|---|---|---|
| Idiopathic Pulmonary Fibrosis (IPF) | Increased BALF-EVs function as carriers for WNT5A, and contribute to the pathogenesis of IPF | Martin-Medina et al.; AJRCCM 2018, Jul 25. |
Asthma/COPD Bronchoconstriction | Mediate leukotriene conversion LTC4-LTD4 | Lukic et al.; J Lipid Res 2016; 57:1659–69 |
| Allergic Asthma | Leukotriene/cytokine production | Torregrosa Paredes et al.; Allergy. 2012 Jul;67(7):911–9 |
| Allergy and vaccination | EVs can potentially induce tolerance | Prado et al.; J. Immunology 2008. 181 |
| Asthma | EV-lipid profile as a biomarker | Hough et al.; Sci Report, 2018 10,340 |
| COPD | EVs from PMN regulate the pathogenesis | Genschmer et al. Cell. 2019 Jan 10 |
| Sarcoidosis | BALF EVs from sarcoidosis patients carry pro-inflammatory effects. | Qazi et al.; Thorax, 2010; 65 |
Lung transplant Acute rejection | The BALF EV profiles are altered in patients with acute rejection | Gregson et al.; AJRCCM 2015, Dec.15 |
| Lung Cancer | BALF EVs contribute to lung cancer growth | Yang et al.: Frontier in Oncology 2019; April 12 |
| Early stage Lung Ca | BALF EVs as a diagnostic marker | Kim et al.: Chest 2016 Oct Vol 150–4 |
| Lung Cancer | Biomarker of cancer growth | Yang et al |
| ARDS | BALF-EV-miRNAs mediate inflammation and ALI | Sheller et al.: J Infectious Dis. 2019. Jan. 19th |
| Lung Injury | BALF-EV-miRNAs mediate sterile stimuli-associated ALI. | Lee et al.: J Immunology 2018 |
| Pneumonia/sepsis | Macrophage-derived EVs regulate inflammation. | Soni et al. Thorax.2016 June 10 |
Pulmonary Hypertension | Exosomal 15-LO2 mediates hypoxia-mediated HTN | Zhang et al. Cell Death Dis. 2018 Oct 3;9(10):1022 |
Fig. 2Flowchart of EV isolation methods. Summary of multiple different protocols for the isolation of EVs. a: Differential centrifugation, b: Density gradient centrifugation, c: Size-exclusion chromatography, d: Commercial kits for polymer precipitation, e: Precipitation with chemicals, f: Immunoprecipitation, g: Ultrafiltration, and h: Microfluidic technologies
Techniques for EV isolation
| Method | Processing time | Advantages | Disadvantages |
|---|---|---|---|
| Differential centrifugation | 140–600 min | Cost Isolation from large volumes Absence of additional chemicals | Equipment (Ultracentrifugation) Complexity Efficiency is affected by the type of rotor |
| Density gradient ultracentrifugation | 250 min–2 days | Pure preparations No contamination with viral particles Absence of additional chemicals | Complexity Equipment (Ultracentrifugation) Loss of sample |
| Size-exclusive chromatography | 1 ml/min + column | Pure preparations Preserves vesicle integrity Prevents EV aggregation | Limitations on sample volume Specialized equipment and column Complexity |
| Commercial kits for polymer precipitation | 30–60 min or overnight | Simple procedure No need additional equipment | Cost (especially for diluted samples, such as urine) Impurities |
| Precipitation with chemicals (polymers, polyethylene glycol, protamine, sodium acetate) | 60–120 min or overnight | Cost Simple procedure Possibility of processing samples with large volume | Contamination with non-EV proteins Retention of chemical or polymer Long duration (sometimes) |
| Immuno-precipitation (CD9, CD63, CD81 or specific cell type marker) | 240 min | Purity and high selectivity | High selectivity Cost Difficulties with detachment of antibodies Analysis of intact vesicles |
| Ultrafiltration (nanomembrane or filters with a pore diameter of 0.8–0.1 μm) | 130 min | Simple procedure Allowing for concurrent processing of many samples No limitations on sample volume | Filter plugging (loss sample) Contamination (proteins) |
| Microfluidic technologies | Rapidness Purity Efficiency | Complexity of devices Additional equipment Cost |
Comparison of EV Characterizing and Analyzing Techniques
| Technique | DLS | NTA | nanoFACS |
|---|---|---|---|
| Feature | Techniques based on the Brownian motion of and light scattering from the particle | Techniques based on the dual forward scatter and single forward scatter | |
| Measure the diffusion coefficient and derive the size from that diffusion coefficient. So both are influenced by shape in the same manner | Enhanced Forward Scatter (eFSC) technology | ||
| Ensemble measurement provides an intensity-based distribution | Particle-by-particle measurement provides a number-based distribution | Expression of certain EV surface epitopes which can be stained by specific fluorescently labeled antibodies | |
| Can provide the % by intensity of particles | Can give the % by number of particles | Valuable tool to study cell-type specific surface proteins or activation markers on exosomes. | |
| To measure particles smaller than 10 nm or larger than micron | Can often provide higher resolution, | To gain insights about EV populations originating from a particular cell type | |